These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9466478)

  • 21. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
    Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
    Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myelodysplastic syndrome/acute myeloid leukemia supervening previously untreated chronic B-lymphocytic leukemia: demonstration of the concomitant presence of two different malignant clones by immunologic and molecular analysis.
    Mitterbauer G; Schwarzmeier J; Mitterbauer M; Jaeger U; Fritsch G; Schwarzinger I
    Ann Hematol; 1997 Apr; 74(4):193-7. PubMed ID: 9174549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of TGFβ in hematopoiesis and myeloid disorders.
    Bataller A; Montalban-Bravo G; Soltysiak KA; Garcia-Manero G
    Leukemia; 2019 May; 33(5):1076-1089. PubMed ID: 30816330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myelodysplastic syndrome in children and adolescents.
    Niemeyer CM; Baumann I
    Semin Hematol; 2008 Jan; 45(1):60-70. PubMed ID: 18179970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases.
    Merlat A; Lai JL; Sterkers Y; Demory JL; Bauters F; Preudhomme C; Fenaux P
    Leukemia; 1999 Feb; 13(2):250-7. PubMed ID: 10025899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDS-related AML.
    Gandini D; De Angeli C; Aguiari G; Manzati E; Lanza F; Pandolfi PP; Cuneo A; Castoldi GL; del Senno L
    Leukemia; 2002 May; 16(5):886-93. PubMed ID: 11986951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular, cytogenetic and genetic abnormalities in MDS and secondary AML.
    Padua RA; McGlynn A; McGlynn H
    Cancer Treat Res; 2001; 108():111-57. PubMed ID: 11702597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear PI-PLC β1 and Myelodysplastic syndromes: from bench to clinics.
    Mongiorgi S; Follo MY; Clissa C; Giardino R; Fini M; Manzoli L; Ramazzotti G; Fiume R; Finelli C; Cocco L
    Curr Top Microbiol Immunol; 2012; 362():235-45. PubMed ID: 23086421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy.
    Rosenthal NS; Farhi DC
    Am J Clin Pathol; 1996 Nov; 106(5):676-9. PubMed ID: 8929481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelodysplastic syndromes: From pathogenesis and prognosis to treatment.
    Fenaux P
    Semin Hematol; 2004 Apr; 41(2 Suppl 4):6-12. PubMed ID: 15190510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myelodysplastic syndromes: molecular pathogenesis and genomic changes.
    Nolte F; Hofmann WK
    Ann Hematol; 2008 Oct; 87(10):777-95. PubMed ID: 18516602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proliferation and differentiation of myelodysplastic CD34+ cells.
    Sawada K
    Leuk Lymphoma; 1996 Jun; 22(1-2):43-51. PubMed ID: 8724527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The genetic and molecular pathogenesis of myelodysplastic syndromes.
    Shallis RM; Ahmad R; Zeidan AM
    Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myelodysplastic syndromes: review of pathophysiology and current novel treatment approaches.
    Warlick ED; Smith BD
    Curr Cancer Drug Targets; 2007 Sep; 7(6):541-58. PubMed ID: 17896920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uncoding the genetic heterogeneity of myelodysplastic syndrome.
    Lindsley RC
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):447-452. PubMed ID: 29222292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute myeloid leukemia and myelodysplasia following intensive chemotherapy for breast cancer.
    Roman-Unfer S; Bitran JD; Hanauer S; Johnson L; Rita D; Booth C; Chen K
    Bone Marrow Transplant; 1995 Jul; 16(1):163-8. PubMed ID: 7581117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary or therapy-related MDS and AML and their chromosome aberrations: important to study but difficult to establish causality.
    Pedersen-Bjergaard J; Andersen MK
    Haematologica; 1998 Jun; 83(6):481-2. PubMed ID: 9676018
    [No Abstract]   [Full Text] [Related]  

  • 39. [Senescent Mesenchymal Stem Cells Contribute to Progression of Myelodysplastic Syndromes-Review].
    Pang YB; Li WW; Luo JM; Ji J; DU X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):942-946. PubMed ID: 29950248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.